The New Ropanasuri Journal of Surgery
Volume 5

Number 2

Article 10

12-18-2020

Management of Uncomplicated Stanford Type B Aortic Dissection
: A Literature Review:
Zamzania A. Shalih
Training Program in Surgery, Department of Surgery, Faculty of Medicine Universitas Indonesia, dr. Cipto
Mangungkusumo General Hospital, Jakarta, zamzaniaanggia@gmail.com

Akhmadu Muradi
Division of Vascular and Endovascular Surgery, Department of Surgery, Faculty of Medicine, Universitas
Indonesia, dr. Cipto Mangunkusumo General Hospital, Jakarta

Follow this and additional works at: https://scholarhub.ui.ac.id/nrjs
Part of the Surgery Commons

Recommended Citation
Shalih, Zamzania A. and Muradi, Akhmadu (2020) "Management of Uncomplicated Stanford Type B Aortic
Dissection : A Literature Review:," The New Ropanasuri Journal of Surgery: Vol. 5 : No. 2 , Article 10.
DOI: 10.7454/nrjs.v5i2.1089
Available at: https://scholarhub.ui.ac.id/nrjs/vol5/iss2/10

This Literature Review is brought to you for free and open access by the Faculty of Medicine at UI Scholars Hub. It
has been accepted for inclusion in The New Ropanasuri Journal of Surgery by an authorized editor of UI Scholars
Hub.

The New Ropanasuri Journal of Surgery 2020 Volume 5 No.2:37–41.

Management of Uncomplicated Stanford Type B Aortic Dissection:
A Literature Review
Zamzania A. Shalih,1 Akhmadu Muradi.2
1. Training Program in Surgery, 2. Division of Vascular and Endovascular Surgery, Department of Surgery, Faculty of Medicine Universitas Indonesia, dr. Cipto Mangunkusumo General
Hospital, Jakarta.
Corresponding author: zamzaniaanggia@gmail.com Received: 17/Aug/2020 Accepted: 13/Dec/2020 Published: 18/Dec/2020
Website: https://scholarhub.ui.ac.id/nrjs/ DOI:10.7454/nrjs.v5i2.1089

Introduction
Type B aortic dissections are approximately 33% of all dissection cases.
Clinically, type B aortic dissection procedure can be divided into the
complicated and uncomplicated dissection. Complicated aortic type B
dissections are patients with one of the symptoms: hypotension, shock,
malperfusion, acute renal failure, hypertension and retractable pain,
aortic rupture, and aortic dilatation, an increase in the size of dissection.
An Uncomplicated type B aortic dissection are patient without these
symptoms during an in-hospital stay. This classification determines the
prognosis and survival of patients ongoing treatment for complicated
aortic dissection, which is lower (50%) compared to the uncomplicated
(90%) dissection.1,2
Hypertension is more prevalent in type B aortic dissection (70%)1;
therefore, the primary treatment of type B aortic dissection is a therapy
that is aimed at lowering blood pressure and cardiac output.
Pharmacological therapy alone can increase the survival rate per year by
≥80%, but with a high long-term morbidity rate (25%-50%). In
comparison, open surgical therapy increases mortality by 30% instead
of pharmacological therapy (10%). Thus, pharmacological therapy is
preferable to treat an uncomplicated type B aortic dissection.3,4
Traditionally, Thoracic Endovascular Aortic Repair (TEVAR) is only
for complicated dissection. However, in the last few decades, with the
advancement of imaging modality and minimally invasive endovascular
intervention, the paradigm for managing uncomplicated type B aortic
dissection has gone through many changes.5
Globally, the incidents are estimated at 3 per 100,000 lives.2 Meanwhile,
the cases of type B aortic dissection at the National Center General
Hospital dr. Cipto Mangunkusumo (RSCM) is found between 1 to 2
times per year. Though relatively infrequent, the mortality is quite high.
Thus, a review of the current management of uncomplicated descending
aortic dissection is required.
Classification
Acute Aortic Dissection (IRAD) is classified as four, i.e., hyperacute,
acute, subacute, and chronic. The hyperacute referred to 0-24 hours,
acute 2-7 days, subacute 8-30 days, and chronic ≥30 days. The division
is related to the loss of elasticity of the intima septum as time progresses,
and the success rate for manipulating dissection decreases. Moreover,
the cumulative survival rate continues to lower across the four-time

groups despite the therapeutic modality: 94-99%, 82-93%, 77-92%, and
73-91%. This division can help decide for early and late treatment in
aortic dissection cases.6
Another classification of type B aortic dissection is complicated and
uncomplicated, related to the presence of complication. Complicated
type B dissection only represents 15-20% of cases; however, the
mortality rate reaches 50% in this group. Meanwhile, the mortality rate
of uncomplicated type dissection is only 10%. Complications of type B
dissection include hemorrhaging, untreatable pain, uncontrollable
hypertension, dissection enlargement, limb and visceral organ
malperfusion, and spinal cord ischemia. Meanwhile, uncomplicated
aortic dissection means a stable patient who shows none of those
complications during the presentation and admission.6
Therapy in the management of aortic dissection
Medical therapy plays an essential role in managing aortic dissection,
both in acute and chronic cases. The therapy's primary goal is to decrease
the friction and pressure on the affected areas by lowering blood pressure
and cardiac contractility.7 The target for systolic blood pressure is 100120 mmHg, which is called permissive hypotension. The therapies to
lower the blood pressure are beta-blockers, angiotensin-converting
enzyme inhibitors, or intravenous angiotensin receptor blockers for
acute dissection.2
For patients with comorbidities such as diabetes or chronic kidney
failure, the blood pressure target is lower than 130/80mmHg, decreasing
heartbeat with a target of 60 beats per minute, and statin administration
to achieve LDL cholesterol levels the blood of below 70mg/dL and stop
smoking.8,9 For chronic phases, the goal of medical therapy is to restrain
the dissection enlargement, control blood pressure below 140/90
mmHg, change lifestyle, and antihypertensives if needed.7 The
administration of statins, calcium channel blockers, and reninangiotensin inhibitors can prevent complications and avoid aortic
enlargement.2
Open surgery
Open surgery on aortic dissection is related to morbidity rate (paraplegia
30-36%) and high mortality (29-50%). For type B aortic dissection,
complications, and the highest mortality of open surgery are at the acute
phase. The mortality rate depends on the patient's age and organ
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dysfunctions, primarily the renal and visceral, caused by ischemia.2,11
The goal of open surgery on aortic dissection is to charge up and replace
dissected segments. Open surgery tends to be left out due to its high
mortality rate, and pharmacological therapy alone can lower the chance
of morbidity and mortality.4,5,11
Hybrid technique
Open surgery technique requires cardiopulmonary bypass and stopping
circulation using hypothermia to identify and cut the intima tear, and
then the re-approximation of intima and adventitia. This technique still
leaves residue and patented false lumen on about 50% of the patients.
This hybrid technique is a combination of surgery and endovascular,
which is expected to resolve the challenges of open surgery. This
technique is recommended on acute type A aortic dissection with
malperfusion. The hybrid technique for type B aortic dissection is the
revascularization of supra-aortic branches/TEVAR and stent graft repair
without surgery (stenting/fenestrated/branched TEVAR).
The revascularization of supra-aortic branches is followed by
endovascular stent graft on an aortic arch, with or without TEVAR
procedure on the descending aorta. Meanwhile, the stent-graft repair
technique has three types of the stent that can be customized, while the
endovascular treatment can be done during surgery (branch cutting) or
after surgery. This hybrid technique poses similar risks to open surgery,
with a mortality rate on 30 days of 30%. The long-term outcome remains
unknown, but this technique may be an alternative for patients who
cannot undergo open surgery and endovascular intervention.12,13
Endovascular treatment
In 1999, TEVAR was an option for the management of type B aortic
dissection but, in 2008, it became the standard for complicated type B
aortic dissection. TEVAR has shown its superiority in managing
complicated type B aortic dissection compared to open surgery as it
lowers the mortality rate significantly on the first 30 days from 29.3% to
2.8%. The TEVAR procedure benefits are that it can be performed on
patients that don't fit the criteria for surgery, has a short procedure time,
causes much less bleeding compared to open surgery, and faster
recovery time. The main goal of TEVAR on aortic dissection is to stop
blood flow to the false lumen by blocking the entrance tear and
redirecting the blood flow to the aortic lumen. The false lumen will
gradually close up and prompts the thrombosis to recover the aorta.2,13
Some notes need to be taken into consideration in the management of
aortic dissection are the time frame (acute, subacute, and chronic), the
location of the intima tear, the size of the aorta, the extent of the segment
of the aortic involvement, the presence of complications and false lumen
status (patent, partial or complete thrombosis). A classification is
developed to keep up with the endovascular action development, called
DISSECT classification system. This classification identifies six
characteristics that influence the choice of therapy, particularly for
endovascular procedures. Characteristics that are considered necessary
include duration, intimal tear, size of the aorta, the segmental extent of
involvement, clinical complications, and thrombosis of the false lumen.
This classification system makes it easy for practitioners to image the
anatomical features that are considered necessary in deciding the
treatment of patients with aortic dissection.14
One of the complications that often occur after TEVAR is endoleak.
Endoleak is defined as a continuous flow of blood that "leaks" into the
saccus aneurisma but outside the graft endoluminal. Endoleak occurs in
10-40% (average 26%) of patients undergoing TEVAR. If undetected,
the endoleak can progress and cause the expansion of the saccus

aneurisma to rupture; the rupture can be fatal. Endoleak is classified into
four types based on the source of the leak between the systemic
circulation and the saccus aneurisma. Type I endoleak is divided into
type Ia if the leak comes from the endograft's proximal end and Ib if the
leak originates from the distal end of the endograft. Endoleak type I is a
type of endoleak which is very dangerous and requires immediate
intervention. Endoleak type II is the most common endoleak and occurs
when there is retrograde blood flow from patent collateral vessels to the
saccus aneurisma. Intervention in type II endoleak is carried out when
expanding the saccus aneurisma by more than 5 mm. Endoleak type III
is divided into IIIa (endograft modular component leak) and IIIb
(endograft fabric leak). Type IV endoleak is the mildest endoleak and
can heal itself without additional treatment, only involving an increase
in the endograft fabric's porosity. Type V endoleak is an endoleak that is
indeterminate with an unidentifiable source of leakage. The
management protocol for type V endoleak is unclear but generally
requires intervention. Type I and III endoleak are defined as high-flow
endoleak and have a high risk of causing saccus aneurysmal rupture.
Endoleak type II is defined as endoleak low-flow. If left untreated, the
endoleak type can lead to large aortic aneurysms that can rupture and
cause heavy bleeding.19,20,21
Based on the study of validity, importance, and ability in the application
of literature, it was found that five studies were suitable and met the rules
of study in answering research questions.
The study by Afifi (2015) published a retrospective cohort study in
patients with acute type B aortic dissection (ATBAD) who received
pharmacological therapy and opened surgical intervention.22 This study
was conducted to analyze the outcome in type B acute aortic dissection
after treatment. All ATBAD patients are divided into complicated and
uncomplicated according to clinical and radiological conditions. The
therapeutic modalities were pharmacology, open surgery, endovascular
intervention, and peripheral vascular bypass. This study was conducted
for thirteen years at Texas Houston Medical School, from January 2001
to June 2014. All uncomplicated and complicated ATBAD patients
received pharmacological therapy. The pharmacological treatment goal
was to lower systolic blood pressure between 100 and 120mmHg with
early symptoms resolution. All patients were subjected to CT or MRI
scans of the chest, abdomen, and pelvis before discharge to assess for
aortic enlargement. Early death was defined as death within 30 days of
admission.
The early mortality rate was 7.6% (34 patients), with premature death in
uncomplicated ATBAD (2.6%, seven patients). There were
readmissions of 20.3%, namely 101 patients with a median time of 3.5
years for the uncomplicated ATBAD group. Of the 101 patients who
underwent readmissions, 12 (11.8%) patients presented with acute or
chronic type A dissection; 7 of them were uncomplicated ATBAD
patients. In the uncomplicated group, 40 patients (15%) required
reintervention. Partially due to hemothorax evacuation, open aortic
aneurysm surgery, and type A aortic dissection repair. The mean followup time was 4.6 years. The survival rates without intervention in the
uncomplicated groups at one year and five years were 84.8% and
62.7%, respectively. The uncomplicated group's overall survival rates at
years 1, 5, and 10 were 91%, 76.6%, and 66.7%.
The study by Brunkwall (2014) published research comparing best
medical treatment (BMT) and BMT + intervention endovascular stent
graft Gore Tag in patients with uncomplicated acute aortic dissection.23
Acute Dissection: Stent graft OR Best medical therapy (ADSORB) trial
is a prospective randomized study. The study was conducted in 17
European centers from December 2008 to December 2010. All patients
received BMT therapy and were randomized to receive either BMT
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alone or BMT and Gore tag stents. BMT therapy is aimed at lowering
blood pressure to <120/80mmHg and close monitoring. The outcome of
this study assessed the status of thrombosis in the false lumen
(incomplete, complete, no thrombosis) and dilatation or rupture of the
aorta for one year. The assessment was carried out before therapy, three
months, and one year after the complaint about maximum actual
diameter, false lumen, and the transverse section's aortic diameter as a
whole. Dissection-related mortality was defined as death within 30 days
after therapy, during treatment, within 30 days after the endovascular
intervention, or due to aortic dissection.
The BMT administration in the two groups was not much different; on
average, they required four or more hypertension drugs. Patients given
the BMT + Gore Tag stent received intervention within 1-14 days after
symptoms. Incomplete, false lumen thrombosis was found in 13 patients
(43%). BMT + Gore Tag and 30 patients (97%) from the BMT group
(p <0.001). Aortic dilatation was observed in 11 patients (37%) in the
BMT + Gore tag group and 14 patients (45%) in the BMT group. There
was no aortic rupture in either group, or there was one case of death with
myocardial infarction, but it was not considered a dissection-related
criterion.
Nienaber (2009) showed the effect of endovascular stent graft as an
adjunct to pharmacological therapy.15 The study was conducted in 7
German, Italian, and French medical centers between November 2003
and 2005. Uncomplicated type B aortic dissection patients of 2- 52
weeks were randomized to receive TEVAR therapy and optimal
medical therapy (OMT) or OMT only. The instrument that was used
was a TALENT stent graft (Medtronic, Inc, Santa Rosa, Calif) that was
adjusted to the anatomy of each patient. Imaging evaluation was carried
out at three months, one year, and two years after intervention. Patients
with an aortic diameter of ≥6cm or with acute complications and
anatomical abnormalities which could not undergo TEVAR >75° or had
complete false lumen thrombosis were excluded from this study. After
a 14-day observation period to see if there were any acute complications
or the occurrence of spontaneous false lumen thrombosis, the patients
were then offered randomization. One hundred forty patients met the
criteria; 72 patients received medical and endovascular therapy, while
68 received medical therapy alone. The mean period from the complaint
to randomization was 39 and 45 days (beginning of the chronic phase).
The mean time from randomization to the endovascular intervention
was 12 days (1 to 29 days). The TEVAR intervention was successfully
performed in 70 patients without open surgical conversion. One stentgraft was placed in 58 patients (82.9%), 2 stent-grafts in 8 patients
(11.4%), and 3 stent-grafts in 4 patients (5.7 %).
The outcome in 30 days was three vascular injuries requiring additional
procedures, three neurological complications (one paraplegia, one
transient paraparesis with left subclavian artery occlusion, and one
stroke). Although most (74%) patients proceeded with ICU care for ±
24 hours, the mean hospital stay in the TEVAR group was eight days.
In addition, a blood pressure of ≤120/80mmHg was achieved in all
patients after one month of randomization and during outpatient visits.
In the 2-year outcome, aortic dilation >60mm was more prevalent in the
OMT group, which was then treated with TEVAR (16.2%) or to open
surgery (4.4%). There were also three cases of spinal injury ischemia
complications: two in the TEVAR group and one in the OMT group.
All patients who were previously in the OMT group and then underwent
the TEVAR intervention showed promising outcomes, without death
and aortic remodeling. The thrombosis process in false lumen increased
after stent-graft placement, with 91.3% complete false lumen
thrombosis and accompanied by aortic remodeling (p <0.001). On the
other hand, OMT administration alone did not show the process of aortic

remodeling and deflating the false lumen; false lumen thrombosis only
occurs in a few cases.
The study by Nienaber (2013) carried out an extension of the INSTEAD
trial to evaluate the long-term outcome of patients with uncomplicated
type B aortic dissection who were treated with TEVAR and OMT and
previously administered OMT therapy alone.24 The endpoint at five
years assessed all causes of death — deaths associated with aortic
disease (rupture, malperfusion, proximal dissection or death within an
hour of onset of symptoms, symptomatic patients without coronary
disease or heart valve disease) and the development of aortic pathology
(assessed by the incidence rate of open conversion or TEVAR group),
endovascular measures or additional surgery, enlargement of the aorta
>5.5cm and the remodeling process. Patients were monitored until
September 30, 2010 (minimum five years, maximum eight years), and
imaging at five years was obtained in 103 patients. Clinical monitoring
showed that systolic blood pressure could be reduced to ≤130 mm Hg
with OMT in 90% of patients. During the five years of monitoring, 93
TEVAR interventions were carried out. In patients who received OMT
alone, there were 14 cases (five emergencies) that subsequently required
TEVAR and four open surgery cases due to enlargement of the false
lumen. In the TEVAR group, seven cases were requiring additional
TEVAR intervention and three open surgery. At the end of 2010,
twenty-seven patients had undergone aortic repair procedures, and 117
patients were survived.
The mortality of >5 years tended to be lower in patients receiving
TEVAR and OMT compared to OMT alone (11.1 ± 3.7% versus 19.3
± 4.8%; p = 0.13). The benefit of TEVAR at survival rates was seen
between 2 and 5 years (100% versus 83.1 ± 4.7%; p = 0.0003), although
at two years follow-up was not very significant (88.9 ± 3.7% versus 97.9
± 2.0%; hazard ratio, 3.96; 95% CI, 0.84–18.6; p = 0.082). In addition,
cases requiring further treatment (TEVAR or open surgery conversion)
were more common in the OMT group than in TEVAR.
All patients previously in the OMT group who experienced rupturing
during follow-up had a tear of >10mm (14 ± 4 mm), similar to patients
who crossed into critical expansion (13 ± 4 mm). Meanwhile, on the
TEVAR group, re-intervention rates were required in two cases. False
lumen thrombosis was present in 90.6% with an aortic remodeling rate
of 79.2% at year five after TEVAR. In contrast, OMT alone failed to
demonstrate actual lumen enlargement or false lumen deflation but
resulted in the aorta's enlargement from 43.6 ± 9.2 to 56.4 ± 6.8 mm (p
<0.0001).
The study by Wang (2019) published a retrospective analytical research
to assess the effectiveness of TEVAR for uncomplicated type B aortic
dissection by evaluating the 30-day outcome for patients with acute (<30
days) and chronic dissections who were divided into the complicated
and uncomplicated aortic dissection.25 Uncomplicated patients were
then differentiated according to the time interval from symptom onset to
receiving TEVAR therapy according to the IRAD distribution; ≤48
hours,> 48 hours to <7 days, ≥7 days to ≤14 days, and> 14 days to <30
days.
The TEVAR procedure successfully closes the entrance tears in 98% of
acute patients and 99% of chronic patients. The 30-day mortality rate
outcome was 7.3%, with a higher trend for acute versus chronic
dissection (9.3% versus 5.2%; p = 0.126). Complications of procedurerelated bone marrow ischemia occurred in 4.4% of acute dissection
patients and in 2.1% of chronic dissection patients (p = 0.261), with a
neurological deficit of 3.4% in acute dissection and 0.5% in chronic
dissection (p = 0.068). Paralysis incidence due to stroke occurred in
2.5% of acute dissection patients and 1.6% in chronic dissection (p =
39
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0.725). Type A retrograde dissection occurred in 1.1% of acute
dissection patients and in 2.6% of chronic dissection patients (p = 0.412).
There was also a lower free reintervention rate in acute dissection than
in chronic dissection (90.7% versus 94.8%; p = 0.13). In acute
dissection, rapid aortic enlargement was more frequent in the group ≥7
days to ≤14 days and >14 days to <30 days compared with that given
therapy within seven days of onset of symptoms (p = 0.042). The 30day reintervention rate for uncomplicated acute dissection was 5.8% at
all time intervals.
There were five selected studies found in PubMed and Cochrane
Library, four studies comparing the pharmacological therapy and
TEVAR with pharmacological therapy alone in uncomplicated type B
aortic dissection patients. One study comparing TEVAR in acute and
chronic type B aortic dissection. To date, pharmacological therapy
remains the primary treatment for uncomplicated type B aortic
dissection. In the study by Afifi et al., pharmacological therapy alone can
prolong long-term survival by 50-70%. The study also states that
patients of uncomplicated type B aortic dissection receiving
pharmacological therapy alone have an early mortality rate <2.2%, and
those who survived to require further intervention at 15.3%.22 In
addition, in the ADSORB trial by Brunkwall et al., there was no early
mortality at 30 days of monitoring uncomplicated dissection patients
who only get pharmacological therapy. This study also states that at least
three different antihypertensive drugs are needed to control this group's
blood pressure.23
The INSTEAD trial by Nienaber et al. showed uncomplicated type B
dissection patients who received pharmacological therapy alone had a
reasonable survival rate (95.2 ± 2.5%) for up to two years. Those who
had aortic enlargement >60mm who subsequently required intervention
occurred at 22.1% of cases (15 of 68 patients), and only 1.4% (one
patient) developed persistent paraplegia/paraparesis.15 However, on the
five-year observation of this study's extension INSTEAD-XL, the risk
level of death due to all causes that were associated with the aortic and
aortic disease progression was higher in patients receiving
pharmacological therapy alone than in those receiving medicaments
therapy and TEVAR, respectively: 11.1% versus 19.3%, 6.9% versus
19.3% and 27% versus 46.1%.24
Complete false lumen thrombosis is one of the indicators of a good
prognosis. On the other hand, partial false lumen thrombosis is an
indicator that can predict dilation of the aorta and eventually form an
aneurysm. According to the ADSORB trial, patients receiving
pharmacological therapy alone had a higher rate of incomplete, false
lumen thrombosis at one year than patients receiving additional
endovascular therapy (97% versus 43%), as well as aortic dilatation
(45% versus 37%).26 INSTEAD and the INSTEAD-XL trials also
stated that the administration of pharmacological therapy alone failed to
show significant signs of aortic healing and thrombus formation in the
false lumen only in a minority of patients at two years of surveillance.
Five years of partial thrombosis was still present in 78% of patients who
received pharmacological therapy alone and aortic enlargement, which
was seen in 66% of patients.
Conversely, the rate of false lumen thrombosis was increased by
TEVAR intervention at 91.3% complete false lumen thrombosis, and
signs of aortic remodeling at two years. At five years of observation,
complete false lumen thrombosis was found in 90.6% of patients, and
signs of aortic remodeling were found in 79.2% of patients after
TEVAR. In addition, the long-term reintervention-free rate was lower in
patients who had received TEVAR intervention.15, 24
The study by Wang et al. compared the outcome of 30 days at the
TEVAR intervention based on the IRAD time classification. They

found no significant difference between demographics, complaints,
mortality, and complications. The 30-day reintervention rate in this study
was 5.8% for acute dissection after early TEVAR, and no significant
difference was found at any time of intervention. One case type A
retrograde dissection in a case that underwent TEVAR intervention for
<48 hours. However, in the ADSORB trial, the TEVAR procedure in
uncomplicated type B dissection patients <2 weeks, the true lumen was
enlarged, the false lumen was reduced, and the aortic diameter was
reduced. In addition, in the INSTEAD-XL study, patients who received
TEVAR were intervened with a median time of 12 days from
randomization in patients with dissection who had been ≥14 days,
reflecting the initial time of the chronic phase. This study revealed a
reduced aortic specific mortality rate (6.9%) and a reduced disease
progression rate (27%) in those receiving TEVAR.23,24,25 Based on these
data, TEVAR therapy is best performed at subacute time intervals; a
procedure in the acute phase can be performed when the risk of
complications is more significant, such as aortic rupture, but intervention
in the acute phase carries a risk for retrograde dissection which may be
due to the fragility of the blood vessels
Clinical Implication
Previously, the management of uncomplicated type B aortic dissection
was only pharmacological therapy, and intervention was carried out
when complications occurred, either endovascular or open surgery.
Pharmacological therapy remains the mainstay of treatment for type B
aortic dissection, with the primary aim of lowering and stabilizing
systolic blood pressure <120mmHg. The current management of
uncomplicated Stanford type B aortic dissection, based on the results of
the literature search, found a trend in the use of endovascular therapy as
a prevention against the incidence of complications of type B aortic
dissection.
The management of TEVAR in particular cases of uncomplicated aortic
dissection is a minimally invasive option with good results, reducing the
early mortality rate to <2.2%, accelerating the occurrence of complete
flagellum thrombosis (91.3%) at two years, and signs of the sign of aortic
remodeling in 79.2% post-TEVAR at five years of observation. The
results of the treatment of TEVAR in uncomplicated type B aortic
dissection require further study
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